GlassScriptPhysician profile
Sushilkumar M Tibrewala
NPI 1457366858
$5,388.19
in general payments reported to CMS, 2019-2025
24 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $42.93 · 2021: $176 · 2022: $477 · 2023: $958 · 2024: $1,909 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608 · Travel and Lodging: $1,100 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.89 |
| Travel and Lodging | $1,100.45 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,400.74 | 2019-2025 | Skyrizi, Rinvoq |
| Boston Scientific Corporation | $1,375.28 | 2019-2024 | Spyglass, Spyglass |
| Janssen Biotech, INC. | $390.30 | 2020-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.72 | 2019-2025 | Xifaxan |
| Endogastric Solutions, INC | $285.70 | 2019-2024 | Esophyx |
| Madrigal Pharmaceuticals | $213.17 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $204.34 | 2022-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $198.25 | 2019-2025 | Entyvio |
| Pfizer INC. | $186.61 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $136.18 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $95.32 | 2024-2025 | Voquezna |
| Medtronic, INC. | $72.21 | 2025 | Endoflip |
| Ardelyx, INC. | $70.35 | 2023-2024 | Ibsrela |
| Redhill Biopharma INC. | $49.71 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $45.62 | 2021-2023 | Suflave |
| Mauna Kea Technologies, INC. | $44.66 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $40.61 | 2021-2022 | |
| Capsovision, INC. | $36.21 | 2023 | Capsocam Plus |
| Daiichi Sankyo INC. | $28.88 | 2022 | |
| Ambu INC. | $20.59 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.42 | 2019 | |
| Celgene Corporation | $12.42 | 2022 | |
| Merck Sharp & Dohme LLC | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushilkumar Tibrewala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.